A
AsymBio
Biotech & Life Sciences · Huangpu, China
End-to-end contract development and manufacturing for biopharmaceuticals. MoreLess
AsymBio is a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock codes: 002821.SZ / 6821.HK). Backed by Asymchem Group's 30 years of experience and global operations, AsymBio delivers one-stop CDMO services from early-stage and process development to toxicology, clinical, and commercial-scale manufacturing. Building on deep antibody-drug conjugate (ADC) experience, AsymBio is expanding into novel drug conjugates (NDCs), including RDCs, AOCs, APCs, BsADCs, and dpADCs, while maintaining comprehensive service capabilities for antibody therapeutics, including monoclonal, bispecific, and multispecific antibodies, and protein-based therapeutics.
Talent graph
AsymBio's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where AsymBio has talent and traffic
team presence
Market sentiment
What the market is saying about AsymBio
An AI-synthesized read of the highest-engagement posts about AsymBio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AsymBio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.